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AbsTrACT
background adenosine- to- inosine rna editing is a 
co- transcriptional/post- transcriptional modification of 
double- stranded rna, catalysed by one of two active 
adenosine deaminases acting on rna (aDars), aDar1 
and aDar2. ADARB1 encodes the enzyme aDar2 that is 
highly expressed in the brain and essential to modulate 
the function of glutamate and serotonin receptors. 
impaired aDar2 editing causes early onset progressive 
epilepsy and premature death in mice. in humans, 
aDar2 dysfunction has been very recently linked to a 
neurodevelopmental disorder with microcephaly and 
epilepsy in four unrelated subjects.
Methods We studied three children from two 
consanguineous families with severe developmental and 
epileptic encephalopathy (Dee) through detailed physical 
and instrumental examinations. exome sequencing 
(es) was used to identify ADARB1 mutations as the 
underlying genetic cause and in vitro assays with 
transiently transfected cells were performed to ascertain 
the impact on aDar2 enzymatic activity and splicing.
results all patients showed global developmental 
delay, intractable early infantile- onset seizures, 
microcephaly, severe- to- profound intellectual disability, 
axial hypotonia and progressive appendicular 
spasticity. es revealed the novel missense c.1889g>a, 
p.(arg630gln) and deletion c.1245_1247+1 del, 
p.(leu415PhefsTer14) variants in ADARB1 
(nM_015833.4). The p.(leu415PhefsTer14) variant 
leads to incorrect splicing resulting in frameshift with a 
premature stop codon and loss of enzyme function. in 
vitro rna editing assays showed that the p.(arg630gln) 
variant resulted in a severe impairment of aDar2 
enzymatic activity.
Conclusion in conclusion, these data support the 
pathogenic role of biallelic ADARB1 variants as the cause 
of a distinctive form of Dee, reinforcing the importance 
of rna editing in brain function and development.
INTroduCTIoN
One of the most widespread forms of RNA modifi-
cation in the human transcriptome is the conversion 
of adenosine- to- inosine (A- to- I), mediated by active 
members of the adenosine deaminases acting on 
RNA (ADAR) family of enzymes. ADARs are highly 
conserved across vertebrates and invertebrates, and 
are essential for normal development.1 2 Mammals 
have three ADAR proteins: ADAR1 (ADAR), 
ADAR2 (ADARB1), which catalyse the A- to- I 
editing in double- stranded RNA (dsRNA) and 
ADAR3 (ADARB2), which is inactive but still binds 
to dsRNA. The editing and RNA- binding activities 
of ADARs affect RNA processing, RNA stability, 
and can even lead to recoding of open reading 
frames, since inosine in a codon is decoded as 
guanosine. The expression of ADARs varies across 
development and tissues in mammals.3
ADAR1 is widely expressed throughout the body 
and is the most highly expressed ADAR outside 
the central nervous system (CNS). Interestingly, 
both biallelic and monoallelic ADAR1 mutations 
resulting in altered editing have been associated 
with autoimmune conditions such as Aicardi- 
Goutières syndrome, dyschromatosis symmetrica 
hereditaria and bilateral striatal necrosis.4–6
ADAR2 and ADAR3 are most highly expressed 
in CNS, with more restricted expression in other 
tissues. ADAR2 is essential for recoding of brain 
pre- mRNAs, modulating the function of glutamate 
and serotonin receptors through the recoding of the 
transcripts of their subunits.1 7 8 In fact, impaired 
ADAR2 editing causes early onset progres-
sive epilepsy and premature death in mice.9 In 
humans, biallelic ADARB1 variants have been very 
recently associated with a severe developmental 
and epileptic encephalopathy (DEE) characterised 
by global developmental delay (DD), severe- to- 
profound intellectual disability (ID), microcephaly, 
epilepsy and limb spasticity.10
MeThods
subjects and samples
In this study, we report three subjects from two 
unrelated consanguineous families with a similar 
severe DEE, in whom exome sequencing (ES) and 
homozygosity mapping were performed to investi-
gate the underlying genetic cause.
exome sequencing
To investigate the genetic cause of the disease in 
these two families, ES of DNA from probands of 
both families was performed. DNA was extracted 
using standard procedures from peripheral blood 
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leucocytes. For family 1, ES and data analysis were performed 
as previously described.11 For family 2, ES and analysis were 
conducted at CENTOGENE.12 The candidate variants were 
confirmed, and segregation analysis was performed by Sanger 
sequencing.
Mutation analysis
In accordance with the recessive mode of inheritance in both 
families, priority was given to rare biallelic functional variants 
with allele frequency <0.001% in public databases, including 
the 1000 Genomes project, NHLBI Exome Variant Server, 
Complete Genomics 69, gnomAD, GME Variome and Iranome 
as well as the in- house database consisting of 12 000 exomes 
and CENTOGENE internal database. After applying the 
above filtering criteria, no plausible compound heterozygous 
or homozygous variants were identified in genes previously 
associated with neurological phenotypes. However, further ES 
data analysis revealed candidate variants in ADARB1 in both 
families.
Cell culture and plasmids
All the cell lines were obtained from the European Collection 
of Authenticated Cell Cultures, and were grown as monolayers 
at 37°C with 5% CO2. HEK 293T were cultured in Minimum 
Essential Medium (MEM) with Earle’s Salts (biosera) supple-
mented with non- essential amino acids (Sigma- Aldrich), 10% 
fetal calf serum (FCS) and penicillin/streptomycin (biosera). 
HeLa were cultured in Dulbecco’s Modified Eagle Medium High 
Glucose (biosera) supplemented with non- essential amino acids, 
10% FCS and penicillin/streptomycin. SH- SY5Y were cultured 
in Ham’s F12 medium and MEM with Earle’s Salts (mixed 1:1, 
biosera) supplemented with non- essential amino acids, 15% 
FCS and penicillin/streptomycin. All the cell lines were grown as 
monolayers at 37°C with 5% CO2.
The FLAG- tagged ADAR2 expression vectors were generated 
by PCR mutagenesis from the respective wild- type plasmids 
as described previously.10 Mutagenic primers containing the 
p.(Arg630Gln) variant were:
Fw: 5’- CAGA AGCA CAGC AGCC AGGG AAGG CCCC CAAC 
TTCA GTGTCA-3’;
Rv: 5’- CTGG CTGC TGTG CTTC TGCA TTGC TGAT GCCA 
CTGA GCAAAGGC-3’.
For the splicing assay, primers with attB cloning sites were 
designed to amplify a minigene that contains the region around 
ADARB1 exons 4 and 5 from human gDNA. The PCR product 
was cloned into pDESTsplice destination vector using Gateway 
Cloning.13 The primers used for the cloning PCR were:
First step Fw: 5’- AAAA AGCA GGCT GCTG TGTT CTAG 
TTGTGG-3’;
First step Rv: 5’- AGAA AGCT GGGT AAGG GATA TTAA 
CACAGG-3’;
Second step Fw: 5’- GGGG ACAA GTTT GTAC AAAA AAGC 
AGGCT-3’;
Second step Rv: 5’- GGGG ACCA CTTT GTAC AAGA AAGC 
TGGGT-3’.
The mutagenic primers used to introduce the 
c.1245_1247+1 del variant into the wild- type splicing reporter 
plasmid were:
Fw: 5’- GCTT TACT TTAA GTTT AGTA AACA AATA AGGA 
CAGGAAG-3’;
Rv: 5’- CTAA ACTT AAAG TAAA GCTC AAGT TGTG TATA 
AAGAAATC-3’.
rNA editing assay and splicing assay
For the editing assay, HEK 293 T cells were co- transfected 
with two plasmids, the ADAR2 expression vector and the RNA 
editing substrate expression vector, and the RNA from trans-
fected cells was isolated as previously described.10 RT- PCR was 
performed with RevertAid RT Kit (Thermo Fisher) according 
to the manufacturer’s instructions with 2.5 µM of oligo(dT)18 
used as a primer. PCR products encompassing the pri- mir- 376a2 
editing site +4 or the Gria2 Q/R editing site were subjected to 
Sanger sequencing, and the peak heights at the editing sites were 
measured from the sequencing chromatograms. Guanosine peak 
(G) represents the edited transcripts and adenosine peak (A) the 
unedited ones. The editing activity was calculated as G/(A+G), 
and the activity of the wild- type protein was set as 100%. Statis-
tical significance of differences between samples was determined 
by two- tailed t- tests. The primers used for the editing assay PCR 
were:
pri- 376a2 Fw: 5’-TGGGCTCCGTCGTCATTTT-3’;
pri- 376a2 Rv: 5’- CCAT CTTT CCAC TTAC CCTGG-3’;
Q/R Fw: 5’-CCTGGTCAGCAGATTTAGC-3’;
Q/R Rv: 5’-CTAACCTCGCCCATTTTCC-3’.
For the splicing assay, the transfection of SH- SY5Y and HeLa 
cells with the splicing reporter plasmid, the RNA isolation and 
the RT- PCR were all performed as described previously.10 The 
primers used for the splicing assay PCR were:
Spl1 (Fw): 5’-TTCTCACTTGGTGGAAGC-3’;
Spl2 (Rv): 5’-CCAGTTGGTAGAGAGAGC-3’.
Immunoblotting
The cell pellet was resuspended in 15–20 µL of lysis buffer 
(10 mM Tris- HCl pH 8, 10 mM EDTA pH 8, 0.1 M NaCl, 2% 
sodium dodecyl sulfate (SDS)) with 1x cOmplete Protease Inhib-
itor (Roche) and lysed for 30 min at 4°C. The lysate was pelleted 
by centrifugation and the clear supernatant used for immuno-
blotting. Protein concentration was measured with Pierce BCA 
Protein Assay Kit (Thermo Fisher). The lysates were boiled for 
5 min in Laemmli buffer prior to electrophoretic separation on 
an 8% polyacrylamide SDS gel and blotting on a nitrocellulose 
membrane.
Primary antibodies used were: rabbit anti- FLAG polyclonal 
antibody (diluted 1:3000; F7425, Sigma- Aldrich), mouse 
anti-α-tubulin monoclonal antibody (diluted 1:8000; T6074, 
Sigma- Aldrich). Secondary antibodies used were: horseradish 
peroxidase (HRP)- conjugated goat anti- rabbit IgG polyclonal 
antibody (diluted 1:80 000; A0545, Sigma- Aldrich), HRP- 
conjugated goat anti- mouse IgG polyclonal antibody (diluted 
1:5000; A4416, Sigma- Aldrich).
Immunofluorescence
HeLa cells were seeded and transfected for immunofluores-
cence as described previously.10 Primary antibody staining was 
performed with rabbit anti- FLAG polyclonal antibody (F7425, 
Sigma- Aldrich) diluted 1:800 in blocking solution. Secondary 
antibody staining was performed with Alexa Fluor 568 goat 
anti- rabbit IgG (H+L) polyclonal secondary antibody (A-11011, 
Thermo Fisher) diluted 1:200 in phosphate- buffered saline with 
0.3 µg/mL 4',6- diamidino-2- phenylindole (DAPI). Samples were 
analysed with upright microscope Zeiss AxioImager.Z2.
data availability
The data supporting the findings of this study are available 
within the article.
 o
n
 August 4, 2020 by guest. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2020-107048 on 27 July 2020. Downloaded from 
3Maroofian R, et al. J Med Genet 2020;0:1–10. doi:10.1136/jmedgenet-2020-107048
Neurogenetics
Figure 1 Family 1: pedigree, segregation analysis, chromatograms, clinical photos, brain Mri and electroencephalogram (eeg) screenshots of patient 
1. (a) Pedigree showing parental consanguinity, the proband (indicated by the arrow), and two similarly affected siblings (not tested). The genotype 
of tested individuals is indicated by + (wild- type) and – (mutated). (B) sanger sequencing chromatograms representative of the segregation of the 
c.1889g>a, p.(arg630gln) variant (nM_015833.4) within the family. (c) clinical pictures of patient 1 at 5.6 years. Dysmorphic features include sloping 
forehead, upslanting palpebral fissures, telecanthus, full cheeks, short philtrum, tented upper lip vermilion, pointed chin and pointed and indented helices. 
Microcephaly, muscle wasting and distal contractures of the upper extremities can also be observed. (D) Brain Mri at 5.6 years (blurred due to involuntary 
movements) shows diffuse cerebral atrophy with loss of subcortical white matter and enlargement of the ventricular system and the subarachnoid spaces. 
corpus callosum hypoplasia is evident in the sagittal T2- weighted section. (e) eeg of patient 1 at different ages. at 9 months, the eeg shows slowing of 
the background cerebral activity and bilateral focal epileptic discharges. at 14 months, frequent multifocal epileptic discharges may be observed. eventually, 
the eeg at 5 years shows recurrent bilateral multifocal epileptiform discharges with secondary generalisation, in the context of a diffuse slowing of the 
background.
resulTs
Patient evaluations
The proband from family 1 (patient 1) is a girl aged 5.6 years 
born to a consanguineous Iraqi family (figure 1A,B). She had two 
similarly affected siblings, a male and a female, who died from 
respiratory infection and distress at the age of 2.5 and 1.5 years, 
respectively. Family history was remarkable for two miscarriages. 
The baby was born at 38 weeks’ gestation after an uneventful 
pregnancy. During the neonatal period, she appeared irritable 
and excessive crying was observed. At the age of 2 weeks, she 
experienced infantile spasms consistent with West syndrome and 
myoclonic jerks, which further progressed to generalised tonic- 
clonic seizures (GTCS). Seizures occurred >10 times a day, lasting 
from 30 s to 2 min. Several antiepileptic drugs (AEDs) were tried 
(including valproic acid, levetiracetam and phenobarbital), but 
resulted ineffective. Electroencephalogram (EEG) at 9 and 14 
months showed bilateral multifocal epileptic discharges in the 
context of a slowed background activity (figure 1E). Brain MRI 
at the age of 3 months showed mild cerebral atrophy and white 
matter abnormalities. Metabolic studies yielded normal results. 
The patient had a profound DD/ID. At the age of 5 years, she 
did not have head control and could not sit, even with support. 
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Visual tracking was very poor and she was non- verbal. She had 
severe microcephaly, with an occipitofrontal circumference 
(OFC) of 45 cm (−4.3 SD). Neurological examination further 
revealed strabismus, axial hypotonia combined with appendic-
ular spasticity, lower extremity clonus, diffuse contractures and 
muscle wasting. Dysmorphic features included epicanthal folds 
with telecanthus, upslanting palpebral fissures, depressed nasal 
bridge, short philtrum, tented upper lip, malocclusion with 
gingival hyperplasia, prominent chin and indented and pointed 
helices (figure 1C). Brain MRI at the age of 5.6 years revealed 
diffuse cerebral atrophy, corpus callosum hypoplasia (CCH) and 
ventricular enlargement (figure 1D). Seizures remained intrac-
table despite multidrug therapy (online supplementary video 1). 
EEG at 5 years showed frequent bilateral multifocal epileptiform 
discharges with secondary generalisation in the context of a 
slow background cerebral activity, suggestive of encephalopathy 
(figure 1E). She had recurrent respiratory infections, likely due 
to dysphagia and aspiration. The patient is currently bed- ridden 
with very limited voluntary movements.
Family 2 consists of two affected sisters aged 6 (patient 2) and 
4.9 years (patient 3) from a consanguineous Egyptian family 
(figure 2A,B). Family history was unremarkable. Both patients 
were born at term after a regular pregnancy. Neonatal course 
was uneventful except for irritability and excessive crying. Their 
psychomotor development was reported normal until the age 
of 2 and 4 months for patients 2 and 3, respectively. After-
wards, severe DD was diagnosed in both siblings. They had no 
head control, visual tracking or response to verbal stimuli. The 
siblings started to experience recurrent seizures at the age of 4–5 
months. Their epileptic phenotype was characterised by tonic 
and myoclonic seizures (including chin myoclonus in patient 
2), occurring on a daily basis and lasting for 1–3 min. Medical 
treatment with several AEDs (including clonazepam, levetirac-
etam, phenytoin, topiramate, valproate and vigabatrin) resulted 
ineffective. Neurological examination revealed axial hypotonia, 
progressive spastic tetraplegia and hyperreflexia in both siblings, 
although patient 3 was less severely affected. Severe micro-
cephaly was also observed, with an OFC of 43 cm (−5.8 SD) 
and 43 cm (−5.1 SD) for patients 2 and 3, respectively. Dysmor-
phic features included high forehead, coarse faces, epicanthal 
folds, hypertelorism, long flat philtrum, puffy cheeks, open bite 
with thick alveolar ridge and gingival hyperplasia (figure 2C). 
Ophthalmological evaluation revealed strabismus and cortical 
blindness. Auditory brainstem responses were normal. In both 
patients, seizures remained intractable at the last follow- up 
examination (online supplementary videos 2 and 3). In patient 2, 
brain MRI at 4 years showed diffuse cerebral atrophy with rele-
vant subcortical white matter involvement. Additional features 
were CCH and bilateral T2- weighted abnormalities in the lenti-
form nucleus. In her sibling, brain MRI at 11 months showed a 
similar generalised cortical and subcortical atrophy (figure 2D). 
EEG revealed slow- wave elements and low- voltage to medium- 
voltage epileptiform activity in both subjects (figure 2E). Exten-
sive metabolic screening including the dosage of organic acid in 
urine, acylcarnitine profile, ammonia and lactate yielded normal 
results.
Identification of the novel ADARB1 variants
In Family 1, the novel homozygous missense variant 
c.1889G>A, p.(Arg630Gln) in exon 8 of ADARB1 was detected 
(chr21:45 220 857 G>A, GRCh38) (figure 3A). This variant is 
located within a ~37 Mb region of homozygosity and is absent 
in publicly available population databases as well as our in- house 
database. The p.(Arg630Gln) variant occurs at a highly conserved 
amino acid residue (GERP: 4.59, CADD: 29.4; figure 3D), 
and segregated with the disease in the family. In silico analysis 
predicts that the missense variant p.(Arg630Gln) is deleterious 
(CADD: 29.4; FATHMM: Pathogenic (0.872061); Mutation-
Assessor: Medium (2.35); MutationTaster: Disease causing (D 
0.99); PolyPhen-2: Probably damaging (1.00); PROVEAN: 
Deleterious (D 0.02); SIFT: Damaging). The affected residue is 
located in the deaminase domain of ADAR2 (figure 3B). Arg630 
lies in the middle of the β9-β10 loop (figure 3C).14 This loop 
partially extends across the RNA- binding surface of the deam-
inase domain, and Arg630 points towards the major groove of 
the dsRNA substrate. Arg630 is highly conserved in all three 
ADAR family members in vertebrates (figure 3D).
In Family 2, ES led to the identification of the novel homo-
zygous deletion c.1245_1247+1 del, p.(Leu415PhefsTer14) 
(chr21:45 182 751delAAAG, GRCh38) in exon 4 and the down-
stream intron of ADARB1 (figure 3A). This 4- bp deletion affects 
the donor splice site in ADARB1 intron 4 (figure 3A) and is 
predicted to result in incorrect splicing of the affected intron.
Impaired AdAr2 editing activity caused by p.(Arg630Gln)
To investigate the functional significance of the ADAR2 variants, 
an in vitro RNA editing assay was performed, as suggested by 
the very recently published paper by Tan et al.10 To assess the 
effects of the p.(Arg630Gln) variant on RNA editing activity, we 
co- transfected the plasmid expressing the FLAG- tagged ADAR2 
variant and the plasmid expressing a known editing substrate 
(either human pri- mir- 376a2 or murine Gria2 Q/R site) into 
HEK 293 T cells for the RNA editing assay.15 16 The effects of 
the variant were tested in each of the two major isoforms of 
ADAR2 protein, ADAR2S (ADAR2a; UniProt ID: P78563-2) and 
ADAR2L (ADAR2b; UniProt ID: P78563-1). To ensure ADAR2 
protein levels were approximately the same in all samples, we 
performed immunoblotting with whole cell lysates from trans-
fected HEK 293T and probed the membranes with anti- FLAG 
antibody (figure 3E). Next, total RNA from transfected cells 
was used for RT- PCR and Sanger sequencing. With both the 
assayed editing substrates, we detected a large decrease in editing 
activity of the ADAR2 p.(Arg630Gln) variants compared with 
the respective wild- type proteins (figure 3F).
p.(Arg630Gln) does not affect AdAr2 subcellular localisation
We further analysed the subcellular localisation of ADAR2 
p.(Arg630Gln). To this end, transiently transfected HeLa 
cells were used for indirect immunofluorescence. We did not 
observe any effect of the p.(Arg630Gln) variant on localisation 
of ADAR2 as both wild- type and mutant proteins showed the 
same localisation pattern (figure 3G). Consistent with previous 
reports, ADAR2 localised to the nucleus and accumulated in the 
nucleoli.17 18
Impaired ADARB1 splicing caused by c.1245_1247+1del
Next, a minigene encompassing the region around ADARB1 
exon 4 and 5 was cloned into pDESTsplice splicing reporter 
plasmid and PCR mutagenesis was used to introduce the 
c.1245_1247+1 del variant (figure 3H).13 This construct was 
then transiently transfected into SH- SY5Y (metastatic neuroblas-
toma) and HeLa (cervical cancer) cells. One day after the trans-
fection, total RNA was isolated, DNase treated and RT- PCR was 
performed to assess potential splicing defects.
The wild- type construct was correctly spliced in SH- SY5Y 
cells, whereas in HeLa cells a fraction of transcripts was 
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Figure 2 Family 2: pedigree, segregation analysis, chromatograms, clinical photos, brain Mri and electroencephalogram (eeg) screenshots of patients 
2 and 3. (a) Pedigree showing multiple consanguinity and the genotypes of tested individuals indicated as + (wild- type) and – (mutated). Paternal 
segregation was not available (na). (B) sanger sequencing chromatograms show the segregation of the c.1245_1247+1 del, p.(leu415PhefsTer14) variant 
(nM_015833.4) in the two affected siblings (patients 2 and 3) and their mother. The non- coding strand of the ADARB1 gene is shown. (c) clinical pictures 
of patients 2 and 3 at the age of 6 and 4.9 years, respectively. Patient 2 has severe axial hypotonia with lack of head control and strabismus. her peculiar 
facial appearance is characterised by sloping forehead, hypertelorism with upslanting palpebral fissures, depressed nasal bridge, triangular nostrils, long 
and flat philtrum, full cheeks, wide mouth with tented upper lip vermilion and malocclusion, and pointed chin. her sister, patient 3, is less severely affected 
and shows milder dysmorphic features which include depressed nasal bridge, full cheeks and long philtrum. in detail, the ogival palate and the gingival 
hypertrophy in patient 3. (D) Brain Mri of patients 2 and 3 at the age of 4 years and 11 months, respectively. in patient 2, brain Mri shows diffuse cerebral 
atrophy with relevant loss of white matter and ventricular dilation. hippocampal atrophy is particularly severe. linear T2- weighted hyperintensities in the 
lentiform nuclei can be observed. The T1- weighted sagittal section shows the considerable corpus callosum hypoplasia. in patient 3, cerebral atrophy is 
predominant in the frontoparietal regions. subcortical white matter is affected but there is a relative sparing of the basal ganglia. There is hypoplasia of the 
corpus callosum, but the ventricular enlargement is less severe. (e) eegs of the affected siblings at the ages of 6 and 4.9 years, respectively. in patient 2, 
there are slow- wave elements and low- voltage to medium- voltage epileptiform activity predominant in frontal region bilaterally. in patient 3, there are slow, 
sharp and low to medium- voltage elements in both hemispheres with multifocal origin.
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Figure 3 Functional assessment of the aDar2 variants. (a) schematic drawing of the nM_015833 transcript of ADARB1 with the previously reported 
variants (in black, upside) and the two variants identified in the current study (in red, down). The splicing junction altered by the c.1245_1247+1 del, 
p.(leu415PhefsTer14) variant is shown in detail. (B) cartoon showing the aDar2 long isoform (aDar2l) nP_056648.1 with the previously (black, upside) 
and currently (red, down) reported variants. The Alu insertion site is delimited by thin diagonal lines in the context of the deaminase domain. The two rna- 
binding domains are indicated as dsrBD1 and dsrBD2. nls, nuclear localisation signal. (c) close- up view of a cartoon model of the aDar2 deaminase 
domain (blue) with double- stranded rna (dsrna) substrate (wheat). arg630 is drawn as sticks; zinc is shown as an orange sphere, ihP as stick model 
(PDB iD: 5eD1). (D) Multiple sequence alignment of aDar1, aDar2 and aDar3 from several vertebrate species is shown (human sequence in bold). (e) 
immunoblots probed with indicated antibodies showing protein levels of Flag- tagged aDar2 wild- type (WT) or p.(arg630gln) after co- transfection of 
heK 293T with plasmids expressing aDar2 and pri- mir- 376a2. lanes with the same labels represent replicates. nc, non- transfected control. (F) graph 
showing editing of two tested substrates by aDar2s or aDar2l proteins in transiently transfected heK 293T. Previously tested variants in black,10 new 
tested variant in red. ratio g/(a+g) is the ratio of the guanosine peak height to the sum of adenosine and guanosine peak heights of the sequencing 
chromatograms. editing levels were normalised to the editing by the WT protein, which is set as 100% (indicated by dashed line). Data represent means±sD 
(n≥3 independent experiments). *P≤0.05, ***p≤0.001. n/a, not available; n.s., not significant. (g) hela cells were transiently transfected with plasmids 
expressing the indicated Flag- tagged proteins and analysed by indirect immunofluorescence. cells were probed with anti- Flag antibody (red channel) with 
DaPi (blue channel) used as a Dna stain. cells with representative staining pattern are displayed. (h) schematic drawing of part of the splicing reporter 
plasmid. ADARB1 exon 4 with two cryptic splice sites is shown in detail. Ins2 stands for rat insulin-2 gene. exons are shown as boxes, introns as lines. The 
positions of primers used for Pcr are indicated below. (i) electrophoretogram of splicing products from hela and sh- sY5Y cells transiently transfected with 
WT or c.1245_1247+1 del splicing reporter plasmid. each band was cut out from the gel and its identity was confirmed by sanger sequencing. reverse 
transcription was performed twice, each time with a different primer (either oligo(dT)18 or a transcript- specific primer spl2). experiment was performed with 
biological triplicates, and a representative agarose gel (with oligo(dT)18 used for reverse transcription) is shown.
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incorrectly spliced due to recognition of the cryptic splice site 
1 (figure 3H,I). This difference is possibly a reflection of the 
different origin of SH- SY5Y (neuronal) and HeLa (epithelial) 
cells. The introduction of c.1245_1247+1 del variant into the 
minigene lead primarily to exon 4 skipping in both cell lines. 
Additionally, two cryptic splice sites inside exon 4 were used in a 
fraction of transcripts originating from the c.1245_1247+1 del 
minigene in both cell lines (figure 3H,I). Regardless of the 
splicing outcome, the effect on translation is similar, as exon 
4 skipping or use of either of the cryptic splice sites causes a 
frameshift with a premature stop codon in ADARB1 mRNA. We 
conclude that the c.1245_1247+1 del mRNA cannot encode 
full- length ADAR2 protein and it is most likely targeted for 
nonsense- mediated decay (NMD).
dIsCussIoN
We have identified two novel biallelic variants in ADARB1, a 
missense and a deletion, segregating in three individuals with a 
severe DEE from two unrelated families. Both of these very rare 
variants result in a loss of function of ADAR2, supporting this 
as the pathogenic mechanism underlying ADARB1- related DEE.
These results are in line with an autosomal recessive pattern 
of inheritance that has been observed in Adar2 null mice. In 
fact, studies in mice elucidating some functions of ADAR2 in 
brain physiology revealed that Adar2 knockout mice die due to 
seizures within 3 weeks after birth, but a single- allele knockout 
of Adar2 is still viable. Similarly, heterozygous ADARB1 variants 
did not lead to epilepsy in the subjects of the above- mentioned 
study, whereas biallelic variants resulted in a severe encephalop-
athy.10 In agreement with these observations, the loss- of- function 
observed/expected upper bound fraction is 0.4 and ADARB1 is 
predicted to be likely associated with a recessive rather than a 
dominant disorder by DOMINO.19
The main molecular pathogenic mechanism underlying 
ADARB1- related encephalopathy is most likely represented by 
the ADAR2- mediated recoding of brain pre- mRNAs. In the 
brain, ADAR2- mediated A- to- I editing recodes the transcripts 
encoding glutamate (eg, GRIA2, GRIK1) and serotonin (eg, 
HTR2C) receptor subunits, modulating their functions.1 7 8 
Consequently, deregulation of A- to- I editing of these transcripts 
has been associated with a wide range of neurological and psychi-
atric disorders.20 21 Of note, the viability of Adar2 null mice is 
restored on insertion of the pre- edited Gria2 R sequence into 
the mouse genome.22 The same lethal phenotype was observed 
in mice with the editing- incompetent allele of Gria2.9 This indi-
cates that the lethality in mice is exclusively mediated by the 
lack of editing of the Gria2 Q/R site. GRIA2 is a subunit of the 
ionotropic α-amino-3- hydroxy-5- methyl-4- isoxazolepropionic 
acid (AMPA) type of glutamate receptor and the ADAR2 editing 
determines the AMPA receptor calcium permeability. In humans, 
heterozygous GRIA2 variants were identified in 28 unrelated 
individuals with DEE.23 These observations are consistent with 
our hypothesis that the deleterious ADARB1 variants manifest 
via GRIA2 Q/R site under- editing.
The under- editing of GRIA2 in ADARB1 patients suggest 
that the early use of the recently developed drug perampanel (a 
selective and non- competitive antagonist of the AMPA receptor) 
might be beneficial in controlling the seizures. In a small study 
with a mouse model of sporadic amyotrophic lateral sclerosis 
(sALS), perampanel administration successfully prevented the 
progressive loss of motor neurons caused by the conditional 
knockout of Adar2 and the subsequent excitotoxicity due to 
Gria2 under- editing.24 The clinical trials of perampanel efficacy 
in treatment of patients with sALS are ongoing.25 This drug is 
currently approved for the treatment of intractable epilepsy and 
could allow a better seizure control in ADARB1 patients. Further-
more, an early intervention on the epilepsy could modify the 
natural history of this condition, possibly decreasing or slowing 
the progression of the encephalopathic changes.26
In this report, we expand the phenotypic characterisation of a 
new form of severe DEE caused by biallelic variants in ADARB1. 
This condition is characterised by profound DD, intractable 
epilepsy, spasticity, and cerebral atrophy (table 1).
At birth, affected children appear healthy and congenital 
microcephaly has been observed in only one case.10 Excessive 
irritability and crying, and feeding difficulties occur in the first 
months of life. Afterwards, a profound DD becomes evident as 
most subjects lack head control, cannot sit even with support 
and are non- verbal. Epilepsy starts in the first year of life, espe-
cially in the first semester. Seizure types include focal, myoclonic, 
tonic and GTCS. In our cohort, patient 1 also showed infantile 
spasms leading to a diagnosis of West syndrome. The response 
to AEDs is very poor with recurrent and intractable seizures 
despite multidrug treatment. EEG features consist of slowing of 
background cerebral activity and multifocal epileptic discharges. 
Seizure evolution is variable, but many patients develop intrac-
table GTCS. Status epilepticus has been reported in two previous 
patients by Tan et al.10 Affected individuals develop progressive 
microcephaly (up to −5.8 SD) and spastic tetraplegia, with very 
limited voluntary movements. A specific facial gestalt cannot be 
recognised, but some dysmorphic features (eg, apparent hyper-
telorism, upslanting palpebral fissures, depressed nasal bridge 
and pointed chin) recur. All our patients showed gingival hyper-
trophy, but this finding might be attributed to phenytoin treat-
ment. While hearing is usually spared, strabismus and cortical 
blindness are common.
As to the neuroimaging features, all affected individuals 
showed a variable combination of severe structural changes of the 
CNS. In line with the very recent report by Tan et al,10 delayed 
myelination and diffuse cerebral atrophy with relevant white 
matter involvement were observed in our cases. Furthermore, 
brain MRI revealed a considerable CCH. Peculiar T2- weighted 
hyperintensities were identified in the lentiform nuclei of patient 
2. Of note, basal ganglia may also be spared in some cases, as 
suggested by the lack of evident atrophic changes in the putamen 
and globus pallidus in patient 3. However, the milder abnormal-
ities observed in this case likely reflect the younger age at MRI, 
as the disease course is progressive. The ongoing monitoring of 
affected individuals will help clarify the evolution of the atrophic 
process over time and the peculiar involvement of the diverse 
cerebral structures. Although non- specific, these neuroimaging 
abnormalities illustrate the severity of this condition and repre-
sent useful clues to support the electro- clinical diagnosis.
A remarkable feature of ADARB1- related DEE is the variable 
expressivity. Although this condition is generally severe (table 1), 
one of the patients very recently reported by Tan et al (individual 
1) was able to stand with support and showed a milder epileptic 
phenotype, with staring spells and few GTCS episodes.10 Fibro-
blasts from this patient appeared to express more ADAR2 than 
control fibroblasts and the editing activity of ADAR2 variants 
from this patient was less affected compared with the rest of the 
cohort. Although this subject had profound DD, microcephaly 
and severe feeding difficulties, his electroclinical features were 
milder than all other known ADARB1 cases. Similar observations 
arise on the neuroimaging aspects, as white matter involvement 
was less severe in the individuals 3 and 4 from Tan et al.10 Future 
studies and the identification of further cases will help better 
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Table 1 Clinical characteristics of the subjects with ADARB1 variants
Family 1 (Iraq) Family 2 (egypt) Tan et al10 (Caucasian, hispanic, Azari)
Pt 1 (IV-7) Pt 2 (III-1) Pt 3 (III-2) 4 pts, 4 families
Age at last FU, sex 5.6 y, F 6 y, F 4.9 y, F Mean 5.2 y, 4 M
Alive + + + + (3), one died at 2 y
Consanguinity + + + + (2)
Previous miscarriages + – – + (1)
Similarly affected siblings + (2, deceased) + (III-2) + (III-1) –
Pregnancy Regular (38 we) Regular (40 we) Regular (38 we) Regular (3), pre- eclampsia (1)
Birth complications – – – –
OFC at birth N/A 33.3 cm (−0.72 SD) 33 cm (−0.7 SD) 0.38 to −2.2 SD (2 N/A)
Neonatal course
Irritability + + + N/A
Excessive crying + + + N/A
Developmental history
Visual tracking Poor – – – (3)
Head control – – – – (3)
Sit with support – – – – (3)
Standing with support – – – – (3)
Walking with support – – – – (4)
Speech – – – – (3), few words (1)
Intellectual disability Profound Profound Profound Profound (2), severe (2)
Feeding difficulties + + + + (4)
Dysmorphic features + + + + (2)
OFC at last FU 45 cm (−4.3 SD) 43 cm (−5.8 SD) 43 cm (−5.1 SD) −3.3 to −4.4 SD (mean −3.8 SD)
Neurological features
Axial hypotonia + + + + (4)
Spastic tetraplegia + + + + (2)
Hyperreflexia + + + + (1)
Sleep disturbance + – – + (1)
Other Bruxism, insomnia – – Tremor (1), staring spells (1), repetitive movements (1)
Vision
Strabismus + + + + (1)
Other – Cortical blindness Cortical blindness Cortical blindness (3)
ABRs N/A Normal Normal Normal (4)
Epilepsy
Onset 15 d 4 mo 5 mo 2–7 mo (mean 4.3)
Type MCS, GTCS, IS TS, MCS TS, MCS FS, TS, GS, GTCS
Frequency, duration Daily, 0.5–2 min Daily, 1–3 min Daily, 1–3 min Weekly to daily
Associated signs Apnoea, staring Head deviation, vomiting Head deviation Eye deviation, twitching, apnoea
EEG MFDs, slow background MFDs Bilateral TPDs MFDs, slow background
Status epilepticus – – – + (2)
Response to AEDs* – – – – (4)
Evolution GTCS (LGS) TS, MCS TS, MCS GTCS
Current status Intractable Intractable Intractable Intractable
Neuroimaging features†
Diffuse cerebral atrophy + + + + (3), temporal lobes (1)
White matter loss + + + + (2)
Delayed myelination – + + + (2)
CCH + + + + (3)
Enlarged ventricles + + + + (3)
Basal ganglia T2- weighted hyperintensity – + – - (3)
Other features Contractures, muscle wasting, 2 
hypopigmented spots on the sternum
PDA – Laryngomalacia (1), plagiocephaly (2), cryptorchidism 
(1), contractures and muscle wasting (1)
Metabolic investigations‡ Normal Normal Normal Normal (4)
*AEDs included clonazepam, levetiracetam, phenytoin, topiramate, valproate and vigabatrin.
†MRI pictures of three out of four patients were available for review.
‡Extended metabolic screening including organic acid in urine, acylcarnitine profile, ammonia and lactate.
ABRs, auditory brain responses; AEDs, antiepileptic drugs; CCH, corpus callosum hypoplasia; d, days; EEG, electroencephalogram; F, female; FS, focal seizures; FU, follow- up; GS, generalised seizures; 
GTCS, generalised tonic- clonic seizures; IS, infantile spasms; LGS, Lennox- Gastaut syndrome; M, male; MCS, myoclonic seizures; MFDs, multifocal discharges; mo, months; N/A, not available; OFCS, 
occipitofrontal circumference; PDA, patent ductus arteriosus; Pts, patients; s, syndrome; TPDs, temporoparietal discharges; TS, tonic seizures; we, weeks; y, years.
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define the phenotypic spectrum and delineate the neuroradio-
logical aspects of this complex disorder.
The variants reported in this study expand and comple-
ment the spectrum of deleterious ADARB1 variants.10 The 
p.(Arg630Gln) variant observed in patient 1 affects a highly 
conserved positively charged residue at the RNA- binding surface 
of the ADAR2 deaminase domain (figure 3C).14 The positive 
charge of the RNA- binding surface is necessary for the inter-
action of ADARs with the negatively charged dsRNA substrate 
backbone. Thus, this variant is likely to disrupt the protein- RNA 
interface, which is consistent with the strong decrease observed 
in the RNA editing activity. Furthermore, arecently published 
study revealed that Arg630 (corresponding to Arg590 in ADAR-
2Sisoform) plays an important role in mediating protein- protein 
interactions inthe asymmetric dimer of ADAR2.27 Therefore, 
the p.(Arg630Gln) variant probably has anegative impact on 
ADAR2 dimerization, which is required for efficient editingof 
some ADAR2 substrates. Other functionally relevant protein- 
protein interactions of ADAR2 couldbe affected by this variant 
as well.28–32 The c.1245_1247+1 del variant causes incorrect 
splicing of ADARB1 minigene transcripts due to exon skipping 
and cryptic splice site activation. Hence, we expect that ADARB1 
mRNAs from patients 2 and 3 all contain a frameshift and a 
premature stop codon. Such mRNAs are most likely targeted for 
NMD.
In conclusion, we contribute to the delineation of ADARB1- 
related DEE phenotype, stressing the progressive course of this 
condition and the most relevant clinical aspects (profound DD/
ID, progressive microcephaly and spastic tetraplegia and intrac-
table epilepsy). The identification of the null c.1245_1247+1 del 
variant and the functional characterisation of the c.1889G>A 
variant supported a loss- of- function pathogenic model. In 
conclusion, these data show the pathogenic role of biallelic 
ADARB1 variants as the cause of a new distinctive DEE in the 
group of RNA editing- related disorders, reinforcing the impor-
tance of RNA editing in brain function and development. Our 
study further suggests that ADARB1 variants should be screened 
in DEE cases tested with ES and that ADARB1 should be included 
in the epileptic encephalopathies next- generation sequencing 
panels.
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